Prev Arrow Stocks

Edwards Lifesciences Corporation ($EW) Stock Forecast: Up 6.6% Today

Morpher AI identified a bullish signal. The stock price may continue to rise based on the momentum of the good news.

What is Edwards Lifesciences Corporation?

Edwards Lifesciences (NYSE: EW) is a company specializing in heart devices, focusing on Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT).

Why is Edwards Lifesciences Corporation going up?

EW stock is up 6.6% on Feb 12, 2025 20:06

  • The company reported strong Q4 sales growth, surpassing consensus estimates and showing a 9% increase year-over-year.
  • TMTT sales surged by 77% in 2023, driven by the adoption of PASCAL and EVOQUE, significantly contributing to the positive overall performance.
  • TAVR sales performed robustly, reaching $1.04B in Q4 with a 5.3% increase year-over-year, additionally boosting the stock's positive movement.
  • Analysts remain confident in Edwards Lifesciences' long-term prospects, which is evident in the positive market sentiment and today's bullish stock movement.

EW Price Chart

EW Technical Analysis

EW News

Heart Devices-Focused Edwards Lifesciences Confident in 2025 Outlook, Analyst Sees Long-Term Strength - Edwards Lifesciences ( NYSE:EW )

Q4 sales rose 9% year-over-year to $1.39B, beating the $1.36B consensus. Adjusted EPS of $0.59 topped estimates of $0.55. TMTT sales surged 77% in 2023 to $352M, driven by PASCAL and EVOQUE adoption. TAVR sales reached $1.04B in Q4, up 5.3% year-over-year.

https://www.benzinga.com/general/health-care/25/02/43672055/heart-devices-focused-edwards-lifesciences-confident-in-2025-outlook-analyst-sees-long-term-s

0 News Article Image Heart Devices-Focused Edwards Lifesciences Confident in 2025 Outlook, Analyst Sees Long-Term Strength - Edwards Lifesciences  ( NYSE:EW )

Edwards Lifesciences Corporation Price History

18.10.2024 - EW Stock was up 3.6%

  • Despite facing multiple securities class action lawsuits and allegations of securities law violations, Edwards Lifesciences (EW) saw a strong bullish movement in the market today.
  • Investors might be optimistic about the company's ability to navigate through the legal challenges and maintain its market position.
  • The bullish trend could also be attributed to positive developments in the company's core business operations or potential market opportunities that investors are anticipating.
  • It appears that market sentiment towards Edwards Lifesciences (EW) remains resilient in the face of legal uncertainties, driving the stock price higher.

30.09.2024 - EW Stock was down 4.7%

  • Lawsuits and alerts about losses appear to have impacted investor confidence in Edwards Lifesciences Corporation (EW).
  • Trading trends show a significant focus on put options, suggesting a bearish sentiment among investors.
  • An upcoming deadline for investors who purchased shares during a specific period may have contributed to the selling pressure on EW stock.
  • Overall, negative news flow and legal actions surrounding EW likely influenced the bearish market movement observed today.

08.09.2024 - EW Stock was up 6.1%

  • The bullish movement in EW could be attributed to investors recognizing the company as a better value option compared to its competitor TFX.
  • Positive sentiment surrounding Edwards Lifesciences' products and potential growth prospects might have contributed to the stock's upward trajectory.
  • The comparison with TFX could have sparked increased interest in EW, leading to higher demand and a bullish market movement.

28.09.2024 - EW Stock was down 2.5%

  • The stock of Edwards Lifesciences Corporation (EW) experienced a strong bearish movement today.
  • The market reacted negatively to the series of investor alerts and class action lawsuit announcements against Edwards Lifesciences Corporation.
  • The legal actions and fraud alerts likely raised concerns among investors, leading to a sell-off of EW shares.
  • The uncertainty surrounding the lawsuits and potential violations of securities laws may have contributed to the bearish sentiment and downward pressure on the stock price.

17.08.2024 - EW Stock was down 2.5%

  • Despite bullish options activity, Edwards Lifesciences (EW) experienced a strong bearish movement today.
  • The discrepancy between the bullish options activity and the bearish market movement could indicate a divergence in sentiment among investors.
  • It's possible that external factors such as broader market trends or specific company news overshadowed the optimistic options activity, leading to the bearish movement in EW's stock.
  • Investors should closely monitor any upcoming developments or news that could provide more clarity on the stock's unexpected performance.

05.08.2024 - EW Stock was down 6.1%

  • There is a notable options frenzy surrounding Edwards Lifesciences, suggesting that well-funded investors are taking a bearish view on the stock.
  • This negativity could be attributed to concerns related to the company's financial performance, potential regulatory challenges, or broader market conditions affecting the healthcare industry.
  • Investors are advised to closely monitor these indicators as they could signify a shift in sentiment towards Edwards Lifesciences, potentially resulting in further downward pressure on the stock price.

04.11.2024 - EW Stock was up 5.1%

  • Today, the positive outlook outlined at an investor conference contributed to the bullish movement in Edwards Lifesciences' stock. The company is anticipated to experience growth in total sales and therapy segments.
  • Despite dealing with investor class action lawsuits and alerts from various law firms, the market appears to be more interested in the company's growth potential and financial prospects.
  • Investors are showing optimism towards the potential expansion in TAVR and TMTT sales, potentially overshadowing the legal hurdles currently faced by the company.
  • The recent market trend indicates that investors are primarily influenced by Edwards Lifesciences' future growth opportunities rather than its ongoing legal challenges, resulting in an upward momentum in the stock price.

04.11.2024 - EW Stock was up 5.6%

  • The bullish movement in EW stock could be attributed to investors gaining confidence in the company's ability to navigate through the legal challenges it is currently facing.
  • Despite the negative news surrounding class action lawsuits and investor losses, the stock's bullish movement suggests that investors may believe the company will successfully address these issues and continue to thrive in its industry.
  • The upcoming deadlines for filing lawsuits may have created a sense of urgency among investors, leading to increased trading activity and a surge in the stock price.
  • It is essential for investors to closely monitor any developments related to the legal proceedings and assess the potential impact on the company's financial performance in the future.

28.00.2025 - EW Stock was up 3.6%

  • Smart money is showing a bullish sentiment by betting big on Edwards Lifesciences options, indicating confidence in the company's future performance.
  • This significant bullish activity from high-rolling investors could be driven by positive developments within the company, such as promising clinical trial results or new product launches.
  • Retail traders should pay attention to this trend as it suggests a potential upward momentum in EW's stock price in the near future.
  • Overall, the strong bullish movement in EW today may be attributed to the optimistic outlook and strategic positioning of institutional investors in the company.

28.00.2025 - EW Stock was up 5.0%

  • Analysts predict a decrease in earnings for Edwards Lifesciences, but significant investment in the company's options indicates a positive market sentiment.
  • The discrepancy between analyst forecasts and market behavior suggests investor anticipation of future growth or positive company developments.
  • The rise in EW's stock price may be linked to the confidence displayed by high-stakes investors in the company's future potential, leading to increased purchasing activity and driving up the stock value.
  • Investor interest in Edwards Lifesciences appears driven by a focus on long-term growth prospects and the company's market positioning, rather than short-term earnings forecasts.

26.06.2024 - EW Stock was down 8.6%

  • Edwards Lifesciences shares plunged 31% after being downgraded by J.P. Morgan and Truist due to concerns about heart valve replacement sales growth.
  • The stock hit a 52-week low, trading at $60.53, reflecting the negative sentiment surrounding the company.
  • Dampened expectations for heart valve replacement sales growth contributed to the stock's sharp decline.
  • The overall market sentiment, particularly in the tech sector, remained in the "Fear" zone, with tech stocks faltering and impacting investor confidence in companies like Edwards Lifesciences.

12.01.2025 - EW Stock was up 6.6%

  • The company reported strong Q4 sales growth, surpassing consensus estimates and showing a 9% increase year-over-year.
  • TMTT sales surged by 77% in 2023, driven by the adoption of PASCAL and EVOQUE, significantly contributing to the positive overall performance.
  • TAVR sales performed robustly, reaching $1.04B in Q4 with a 5.3% increase year-over-year, additionally boosting the stock's positive movement.
  • Analysts remain confident in Edwards Lifesciences' long-term prospects, which is evident in the positive market sentiment and today's bullish stock movement.
i
Disclaimer
Morpher is not liable for the content of the AI investment insights. Like most GPT-powered tools, these summaries may contain AI hallucinations and inaccurate information. Morpher is not presenting you with any investment advice. All investments involve risk, and the past performance of a security, industry, sector, market, or financial product does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. Such decisions should be based solely on an evaluation of their financial circumstances, investment objectives, risk tolerance, and liquidity needs. These summaries do not constitute investment advice.